Treats complicated urinary tract infections (cUTI) including pyelonephritis caused by…. Sold as Zaynich. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Cefepime Hydrochloride; Zidebactam (sold as Zaynich), first approved May 29, 2026, with 0 new uses approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| Cefepime-Zidebactam Versus Ceftazidime-Avibactam With or Without Colistin for Hospital-Acquired or Ventilator-Associated Bacterial PneumoniaHospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP) · Wockhardt | Phase 3 | Not yet recruiting | Oct 21, 2026 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| May 29, 2026 | ZaynichNDA 220787 · New molecular entity, new combination | Wockhardt Bio AG | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA